Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation

Launched by ERASMUS MEDICAL CENTER · Jan 17, 2014

Keywords

ClinConnect Summary

Rationale: Propofol, a rapidly acting anaesthetic agent, is currently used unlicensed in the clinical care of (preterm) neonates as sedative for endotracheal intubation. Neonates receive the same propofol doses per kg bodyweight, independent of their developmental stage (gestational age, postnatal age), morbidity, co-medication, etc. This is related to a high failure rate of intubation attempts and leads to hypotension in around 40 percent of patients. Propofol research in newborn infants is on the recently published priority drug research list of the European Medicines Agency (EMA). Propof...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• All neonates admitted to the two participating intensive care units:
• • Less than 28 days postnatal age
• • Who need endotracheal intubation
• Exclusion Criteria:
• Patients with:
• • Major congenital anomalies or neurological disorders,
• • Neonates with an abnormal upper airway,
• • Those receiving continuous sedatives or opioids, and
• • Those whose mothers received sedatives or opioids before or during delivery will be excluded during the first 2 days of life.